Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
Incyte Corporation
Sahlgrenska University Hospital
Federation Francophone de Cancerologie Digestive
Merck Sharp & Dohme LLC
Xiamen University